Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Circulation

• Publication date

  1997-11-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.96.10.3396PMID 9396433
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study.

  1996cited by this paper
• Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind

  1996cited by this paper
• Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study.

  1996cited by this paper
• Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial)☆

  1996cited by this paper
• The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome.

  1995cited by this paper
• Low Molecular Weight Heparin in Prevention of Restenosis After Angioplasty: Results of Enoxaparin Restenosis (ERA) Trial

  1994cited by this paper
• Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model.

  1994cited by this paper
• Discordant results of visual and quantitative estimates of stenosis severity before and after coronary angioplasty.

  1993cited by this paper
• Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low‐Molecular‐Weight Heparin

  1992cited by this paper
• Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty.

  1990cited by this paper
• Restenosis After Coronary Angioplasty: Potential Biologic Determinants and Role of Intimal Hyperplasia

  1989cited by this paper
• Heparin interactions with cultured human vascular endothelial and smooth muscle cells: Incidence on vascular smooth muscle cell proliferation

  1989cited by this paper
• Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty.

  1989cited by this paper
• Regulation of Vascular Smooth Muscle Cell Growth by Heparin and Heparan Sulfates

  1987cited by this paper
• Heparin inhibition of smooth muscle cell proliferation: A cellular site of action

  1986cited by this paper
• Bioavailability and antagonization of the low molecular weight heparin CY 216 in man.

  1986cited by this paper
• The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

  1985cited by this paper
• Development of Heparin Fractions: Some Overlooked Considerations

  1985cited by this paper
• Cultured endothelial cells produce heparinlike inhibitor of smooth muscle cell growth

  1981cited by this paper
• Suppression by heparin of smooth muscle cell proliferation in injured arteries

  1977cited by this paper

• The quest for effective pharmacological suppression of neointimal hyperplasia.

  2020cites this paper
• A Four-Year Follow-Up Randomized Comparison of Coronary Stent Implantation and Balloon Angioplasty in the Treatment of De Novo Coronary Artery Lesions ( START ) A Four-Year Follow-up

  2016cites this paper
• Effects of enoxaparin and dalteparin on proliferation and migration of patient-derived vascular smooth muscle cells.

  2014cites this paper
• Intimal Hyperplasia. Experimental and Clinical Studies

  2014cites this paper
• Models for the Study of Atherosclerosis and Thrombosis

  2013cites this paper
• In stent restenosis and thrombosis assessment after EP224283 injection in a rat model.

  2013cites this paper
• Targeted Treatments for Restenosis and Vein Graft Disease

  2012cites this paper
• Resténose intra-stent : évaluation de nouvelles thérapeutiques in vivo et élaboration d’un modèle in vitro hémodynamique

  2012cites this paper
• A critical review of the efficacy and safety in the use of low-molecular-weight heparin in acute ST-elevation myocardial infarction: a Bayesan approach.

  2011cites this paper
• Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• [Low molecular weight heparin in atherothrombotic cardiovascular diseases. Value in coronary disease, ischemic stroke and peripheral arterial occlusive disease].

  2008cites this paper
• Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial.

  2006cites this paper
• [The coagulation cascade--clinical implications].

  2005cites this paper
• Long-term inhibition of intimal hyperplasia using vascular photodynamic therapy in balloon-injured carotid arteries

  2005cites this paper
• Die Gerinnungskaskade—Mechanismen und klinische Implikationen

  2005cites this paper
• Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems.

  2004cites this paper
• Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cites this paper
• Perivascular delivery of neomycin inhibits the activation of NF-κB and MAPK pathways, and prevents neointimal hyperplasia and stenosis after arterial injury

  2004cites this paper
• Stents in der Arteria femoralis: Hilfe oder Problem?

  2003cites this paper
• Nadroparina cálcica y clopidogrel en pacientes sometidos a intervención coronaria percutánea con colocación de stents

  2003cites this paper
• Clinical parameters and functional tests are not predictive for in-stent restenosis

  2003cites this paper
• Post-interventional arterial remodelling: from the clinic to the molecular bases. Proceedings of the 1st International Workshop, Naples, October 2002.

  2003cites this paper
• Stent Restenosis Model Low Molecular Weight Fucoidan Prevents Neointimal Hyperplasia in Rabbit Iliac Artery

  2002cites this paper
• Low Molecular Weight Fucoidan Prevents Neointimal Hyperplasia in Rabbit Iliac Artery In-Stent Restenosis Model

  2002cites this paper
• A chemically modified dextran inhibits smooth muscle cell growth in vitro and intimal in stent hyperplasia in vivo.

  2002cites this paper
• Vascular restenosis. Basic science and clinical implications.

  2002cites this paper
• Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A.

  2001cites this paper
• Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris

  2001cites this paper
• Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy.

  2001cites this paper
• Pharmacological treatment for prevention of restenosis

  2001cites this paper
• Current approaches to therapy for vascular injury

  2001cites this paper
• Overview of therapies for prevention of restenosis after coronary interventions.

  2001cites this paper
• Potential Use of a Low-Molecular-Weight Heparin to Prevent Restenosis in Patients with Extensive Wall Damage Following Peripheral Angioplasty

  2001cites this paper
• New Strategies to Prevent Restenosis

  2001cites this paper
• Effects of probucol on rat carotid artery responses to balloon catheter injury.

  2001cites this paper
• Niedermolekulare Heparine in der Kardiologie

  2001cites this paper
• Anti-Human von Willebrand Factor Monoclonal Antibody AJvW-2 Prevents Thrombus Deposition and Neointima Formation After Balloon Injury in Guinea Pigs

  2000cites this paper
• Novel approaches for the prevention of restenosis

  2000cites this paper
• Local drug delivery: an emerging approach in the treatment of restenosis

  2000cites this paper
• Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study.

  2000cites this paper
• Local delivery of ceramide for restenosis: is there a future for lipid therapy?

  2000cites this paper
• [Antithrombotic therapy in acute coronary syndrome].

  2000cites this paper
• Deposition and Neointima Formation After Balloon Injury in Guinea Pigs Anti-Human von Willebrand Factor Monoclonal Antibody AJvW-2 Prevents Thrombus

  2000cites this paper
• Farmakologiczne próby zapobiegania restenozie

  2000cites this paper
• Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction.

  2000cites this paper
• Low molecular weight heparins

  2000cites this paper
• Low molecular weight heparins for arterial thrombosis

  2000cites this paper
• Clinical and Angiographic Outcomes: Subcutaneous Nadroparin versus Ticlopidine after Coronary Stenting

  1999cites this paper
• Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up.

  1999cites this paper
• Low Molecular Weight Heparins in the Cardiac Catheterization Laboratory

  1999cites this paper
• Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty.

  1999cites this paper
• Should the emergence of new agents change the management of patients with acute coronary syndromes without ST-segment elevation?

  1999cites this paper
• PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon.

  1999cites this paper
• [Practice guidelines of the Spanish Society of Cardiology. Recommendations for the use of antithrombotic treatment in cardiology].

  1999cites this paper
• Clinical differentiation of low molecular weight heparins.

  1999cites this paper
• Guías de actuación clínica de la Sociedad Española de Cardiología. Recomendaciones para el uso del tratamiento antitrombótico en cardiología

  1999cites this paper
• The Utility of Animal Models in the Preclinical Study of Interventions to Prevent Human Coronary Artery Restenosis: Analysis and Recommendations

  1999cites this paper
• The use of low-molecular-weight heparins in cardiovascular disease.

  1998cites this paper
• Periprocedural routines of coronary angioplasty--extreme diversity with unrevealed consequences.

  1998cites this paper
• Pharmacological Approaches to the Prevention of Restenosis After Coronary Angioplasty

  1998cites this paper
• Anticoagulation in interventional cardiology: optimizing patient outcome.

  1998cites this paper